Azitra (AZTR) Stock News

Azitra (NYSE American: AZTR) on Nov. 7, 2025 denied a circulated report that it had priced a $44 million registered direct offering. The company said the report is false and urged investors to rely only on information issued through its official channels. Azitra also said it is taking steps to identify the source of the false report.

Azitra (NYSE: AZTR) announced positive preclinical results for ATR-01 (ATR01-616), an engineered S. epidermidis strain designed to secrete functional human filaggrin to treat ichthyosis vulgaris.

Key findings reported: ATR01-616 secreted functional filaggrin in vitro, delivered filaggrin through the human stratum corneum (delivery below the barrier, p < 0.05), and significantly reduced transepidermal water loss in a damaged pig skin model (p < 0.002).

Azitra plans a path toward first-in-human studies and aims to submit an IND in 2026; detailed data will be presented at BIO-Europe, November 3–5, 2025.

Azitra (NYSE American: AZTR) announced that Travis Whitfill, Ph.D., co-founder and COO, will appear on a Dermatologic Rare Disease Panel at the Maxim Growth Summit in New York City on October 22, 2025 at 8:30 AM EDT.

The panel will discuss Netherton syndrome and Recessive Epidermolysis Bullosa (RDEB). Azitra's lead program, ATR-12, is in a Phase 1b trial in adult Netherton syndrome patients and uses an engineered strain of S. epidermidis to deliver LEKTI topically. Azitra also highlighted ATR-04, an engineered S. epidermidis program for EGFR inhibitor associated rash with FDA Fast Track designation and an open IND.

Azitra (NYSE American: AZTR) received a notice of non-compliance from NYSE American on October 3, 2025 under Section 1003(a)(ii).

The rule requires listed companies with recent losses to have $4 million or more in stockholders' equity. Azitra has until October 31, 2025 to file a Plan to regain compliance by April 1, 2027. The company says it will timely submit a Plan, is exploring multiple funding avenues, and intends to complete one or more transactions to achieve compliance. Receipt of the notice does not affect current listing or trading or SEC reporting.

Azitra is a clinical-stage dermatology company with lead programs ATR-12 (Phase 1b) and ATR-04 (FDA Fast Track; open IND) and a microbial library of ~1,500 strains.

Azitra (NYSE American: AZTR), a clinical stage biopharmaceutical company specializing in precision dermatology, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. Chief Operating Officer Travis Whitfill will deliver a virtual presentation on September 8, 2025, at 7:00 AM ET.

The presentation will highlight recent developments, including promising safety results from the Phase 1b trial of ATR-12 for Netherton syndrome and the initiation of patient dosing in the Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated dermal toxicity. Dr. Whitfill will also conduct one-on-one meetings with investors and potential partners during the conference.

Azitra (NYSE American: AZTR) has initiated dosing in a Phase 1/2 clinical trial for ATR04-484, a topical live biotherapeutic treatment targeting EGFR inhibitor (EGFRi)-associated rash. The condition affects approximately 150,000 people annually in the U.S. and has received FDA Fast Track designation.

The multicenter, randomized, double-blind, vehicle-controlled study (NCT06830863) will evaluate ATR04-484's safety and tolerability in adult patients. The treatment addresses a critical medical need, as EGFRi-associated rash affects 50-80% of cancer patients receiving EGFR inhibitor treatments, often leading to cancer treatment interruption or discontinuation.

ATR04-484 is derived from a specially engineered Staphylococcus epidermidis strain, designed to reduce IL-36γ and S. aureus levels, which are elevated in affected patients.

Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company, reported Q2 2025 financial results and business updates. The company achieved 50% enrollment in Phase 1b trial of ATR-12 for Netherton syndrome, showing promising safety data in the first five patients. Additionally, Azitra secured a $20 million equity line of credit from Alumni Capital LP.

The company's pipeline includes ATR-04, targeting EGFRi-associated rash affecting approximately 150,000 US patients annually. Key upcoming milestones include first patient dosing in ATR-04's Phase 1/2 trial in Q3 2025 and ATR-12's Phase 1b topline data in Q1 2026. Financial results show R&D expenses of $1.4 million, G&A expenses of $1.5 million, and a net loss of $2.9 million, with cash position at $1.0 million.

Azitra (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced a 1-for-6.66 reverse stock split effective August 21, 2025. The company's common stock will continue trading under the symbol "AZTR" on the NYSE American with a new CUSIP number 05479L302.

The reverse split will reduce Azitra's outstanding shares from 23,476,354 to approximately 3,524,978. Stockholders will receive cash in lieu of fractional shares, calculated based on the average closing prices for the five trading days before the split. The split will proportionally adjust equity awards and warrants, including their exercise prices.

["Will help maintain NYSE American listing requirements", "No change to stockholder's percentage ownership in the company", "Stockholders automatically receive cash for fractional shares"]

Azitra (NYSE: AZTR) reported positive initial safety data from its Phase 1b trial of ATR12-351, a live biotherapeutic candidate for Netherton syndrome, a rare genetic skin disorder affecting 1 in 200,000 people. The trial, now 50% enrolled with six patients dosed, shows ATR12-351 has been generally safe and well-tolerated when applied topically. The treatment aims to deliver engineered S. epidermidis bacteria to replace deficient LEKTI protein in the skin. While some mild to moderate application site reactions were observed, these were transient and occurred bilaterally, suggesting they were not drug-related. No severe or serious adverse events have been reported. The trial remains blinded, and efficacy data is not yet available. ATR12-351 represents a potential breakthrough for Netherton syndrome, which currently has no cure and limited treatment options.